Zobrazeno 1 - 6
of 6
pro vyhledávání: '"Maho Tatsumi"'
Autor:
Koichi Kitagawa, Maho Tatsumi, Mako Kato, Shota Komai, Hazuki Doi, Yoshiko Hashii, Takane Katayama, Masato Fujisawa, Toshiro Shirakawa
Publikováno v:
Molecular Therapy: Oncolytics, Vol 22, Iss , Pp 592-603 (2021)
Cancer immunotherapy using immune-checkpoint inhibitors (ICIs) such as PD-1/PD-L1 inhibitors has been well established for various types of cancer. Monotherapy with ICIs, however, can achieve a durable response in only a subset of patients. There is
Externí odkaz:
https://doaj.org/article/3b9793af28f243d7872de85b30098864
Autor:
Toshiro Shirakawa, Masato Fujisawa, Yoshiko Hashii, Takane Katayama, Masahide Kadowaki, Maho Tatsumi, Reina Gonoi, Koichi Kitagawa
Previously, we constructed a recombinant Bifidobacterium longum displaying a partial mouse Wilms' tumor 1 (WT1) protein (B. longum 420) as an oral cancer vaccine using a bacterial vector and demonstrated that oral administration of B. longum 420 sign
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8126f49fcb6001e4d3bd6cf10226d6ab
https://doi.org/10.1158/1535-7163.c.6538372
https://doi.org/10.1158/1535-7163.c.6538372
Autor:
Toshiro Shirakawa, Masato Fujisawa, Yoshiko Hashii, Takane Katayama, Masahide Kadowaki, Maho Tatsumi, Reina Gonoi, Koichi Kitagawa
Supplementary Fig. S1. Representative dot blots of Intracellular cytokine staining (ICCS) in Figure 1B. After vaccination, mice splenocytes were obtained and re-stimulated with TRAMP-C2 in vitro. ICCS was performed for IFN-γ, IL-2 and TNF-α-produci
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::bc6bd74488208255fb9bfd80e7f2dc51
https://doi.org/10.1158/1535-7163.22506331.v1
https://doi.org/10.1158/1535-7163.22506331.v1
Autor:
Yoshiko Hashii, Takane Katayama, Masato Fujisawa, Maho Tatsumi, Toshiro Shirakawa, Hazuki Doi, Koichi Kitagawa, Mako Kato, Shota Komai
Publikováno v:
Molecular Therapy Oncolytics
Molecular Therapy: Oncolytics, Vol 22, Iss, Pp 592-603 (2021)
Molecular Therapy: Oncolytics, Vol 22, Iss, Pp 592-603 (2021)
Cancer immunotherapy using immune-checkpoint inhibitors (ICIs) such as PD-1/PD-L1 inhibitors has been well established for various types of cancer. Monotherapy with ICIs, however, can achieve a durable response in only a subset of patients. There is
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e58ad51d00d8f7c504426a591fe31ce7
http://europepmc.org/articles/PMC8449024
http://europepmc.org/articles/PMC8449024
Autor:
Takane Katayama, Koichi Kitagawa, Toshiro Shirakawa, Yoshiko Hashii, Reina Gonoi, Masahide Kadowaki, Maho Tatsumi, Masato Fujisawa
Publikováno v:
Molecular cancer therapeutics. 18(5)
Previously, we constructed a recombinant Bifidobacterium longum displaying a partial mouse Wilms' tumor 1 (WT1) protein (B. longum 420) as an oral cancer vaccine using a bacterial vector and demonstrated that oral administration of B. longum 420 sign
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a19948328f84c9bafda0a429119fac78
https://pubmed.ncbi.nlm.nih.gov/30824610
https://pubmed.ncbi.nlm.nih.gov/30824610
Autor:
Shota Komai, Yoshiko Hashii, Takane Katayama, Koichi Kitagawa, Toshiro Shirakawa, Mako Kato, Maho Tatsumi
Publikováno v:
Cancer Immunology Research. 7:B114-B114
Nowadays, cancer immunotherapies such as immune-checkpoint inhibitors, chimeric antigen receptor T-cells and cancer vaccines have achieved great success in cancer therapy. Nevertheless, increasing cancer antigen-specific immune responses is necessary
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::3e184046678bd2af33001ed3886ac8d7
https://doi.org/10.1158/2326-6074.cricimteatiaacr18-b114
https://doi.org/10.1158/2326-6074.cricimteatiaacr18-b114